Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

Tempus and Vanderbilt-Ingram Cancer Center Announce Data Initiative to Improve Outcomes for Cancer Patients

NEWS

CHICAGO, Jan. 04, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Vanderbilt-Ingram Cancer Center (VICC) have announced a new collaboration to improve outcomes for cancer patients.

As part of the initial research project, Tempus will use its Tempus O platform to ingest and structure clinical data from the cancer center’s electronic health record. Tempus also will provide next generation sequencing and analysis for a subset of patients in order to identify actionable gene alterations.

“The ability to synthesize and make sense of clinical and molecular data is key to personalized medicine efforts,” said Eric Lefkofsky, Founder and CEO at Tempus. “We are pleased to bring our state-of the-art solution to the team at Vanderbilt-Ingram Cancer Center and other top academic centers, hospital systems, associations, and health care providers across the country. The Tempus platform will unlock critical data, accelerating discovery and ultimately improving patient care.”

In oncology, and across healthcare more broadly, datasets are small and sometimes disorganized. In order to usher in the age of precision medicine, Tempus built a series of data pipelines to collect, cleanse, and analyze data, at scale. These data pipelines in turn are powering a variety of clinical and research applications to drive clinical decision support and leading-edge academic research.

“Empowering Vanderbilt-Ingram researchers and physicians with data, tools and evidence to help inform care and accelerate discoveries that benefit patients is a top priority,” said Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center and director of VICC. “Collaborating with Tempus will allow the Vanderbilt-Ingram team to gain a deeper understanding of a patient’s cancer and its genetic and molecular drivers, with a goal of improving patient outcomes.”

VICC is the only National Cancer Institute-designated Comprehensive Cancer Center in Tennessee that conducts basic, translational and clinical research and offers adult and pediatric oncology treatment. The medical center is a member of the National Comprehensive Cancer Network along with 26 other leading centers working together to improve the quality and effectiveness of cancer care.

About Tempus:

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com and follow us on Facebook (Tempus Labs) and Twitter (@TempusLabs). For more information on Eric Lefkofsky, visit lefkofsky.com.